Stentex
Business Opportunity Assessment Report

Company Snapshot

Stentex LLC is a Russia-based medical device manufacturer, jointly established by Medtronic (USA) and Renova Group (Russia), specializing in coronary stents and interventional cardiology devices. It operates as an OEM/ODM hybrid—designing, manufacturing, and clinically validating high-precision cardiovascular implants and delivery systems. Its supply chain is tightly concentrated: 100% of documented export activity over the past two years targets India, with all shipments routed via Delhi-based air cargo facilities. A notable acceleration occurred in Q3 2025, when monthly transaction count surged from 53 to 1,409—indicating rapid commercial scale-up or regulatory market entry.

Company Attribute Information

Trade Trend Analysis

Data解读: Transaction volume and frequency show extreme temporal concentration—93% of total documented transactions occurred in just three months (Sep–Dec 2025), with September alone accounting for 86% of total transaction count. This reflects either a phased regulatory approval rollout in India or fulfillment of a large initial procurement contract. The absence of earlier trade data suggests recent market entry rather than gradual expansion. This pattern signals high execution velocity but also dependency on a single contractual or regulatory milestone—making near-term performance sensitive to policy continuity in the destination market.

Trade Partner Analysis

Data解读: Trade is fully bifurcated between two Indian partners—TransHealth Pvt Ltd (91.3% share) and Translumina Therapeutics LLP (8.7%). Both are newly engaged (‘Added’ status), with zero overlap in historical trade records prior to 2025. Their complementary positioning—TransHealth as primary distributor, Translumina as specialized therapeutics partner—suggests a dual-channel go-to-market strategy aligned with India’s tiered healthcare infrastructure. This extreme partner concentration introduces operational resilience risk: any disruption at TransHealth would immediately halt >90% of documented revenue flow.

HS Code Analysis

Data解读: HS 90183990 (other electro-medical apparatus, incl. coronary stents) dominates trade—representing 84.9% of all transactions—confirming stent-centric product focus. Secondary codes (90219090: catheters; 90213900: guidewires) reflect full procedural kit bundling. Notably, HS 90314900 (measuring/testing instruments) and 39269099 (plastic fittings) appear sporadically—likely indicating R&D validation tools or packaging components, not core exports. This coding structure confirms clinical-grade manufacturing capability—not just assembly—and aligns precisely with Stentex’s stated mission of delivering ‘clinically proven therapies’.

Trade Region Analysis

Data解读: India accounts for 100% of documented export activity—no diversification across other geographies appears in customs records. This is consistent with India’s aggressive domestic medical device localization policy (Production Linked Incentive Scheme for Medical Devices, launched 2021), which offers up to 10% financial incentive for local manufacturing or technology transfer partnerships—precisely matching Stentex’s Medtronic-Renova joint venture model. Such singular regional focus reflects strategic alignment with national industrial policy—but implies zero buffer against India-specific regulatory, tariff, or reimbursement shifts.

Export Port Analysis

Data解读: Over 85% of shipments clear through Delhi Air Cargo—a dedicated facility for time-sensitive, temperature-controlled, and high-value medical consignments. The remaining 14% use general Delhi port entries, likely for lower-priority or non-sterile components. This port selection strongly indicates prioritization of speed-to-clinic and compliance with India’s strict import timelines for Class C/D medical devices. Heavy reliance on a single air cargo hub creates vulnerability to flight cancellations, customs clearance delays, or capacity constraints—especially during peak healthcare procurement cycles (e.g., FY-end in March).

Contact Information

• Official Website: https://www.stentex.ru/
• LinkedIn: https://www.linkedin.com/company/stentex
• Email: info@stentex.ru
• Headquarters Address: Moscow, Russia (confirmed via employee profiles and domain WHOIS)

Company Trade Summary

• Fully India-focused export strategy with zero geographic diversification in documented trade.
• Core product portfolio strictly aligned with Class C/D cardiovascular implants—validated by HS code dominance (90183990).
• Rapid commercial ramp-up confirmed: 1,639 transactions in <4 months after market entry.
• Dual-partner distribution model deployed—TransHealth as primary channel, Translumina as clinical-specialty complement.
• End-to-end OEM capability demonstrated: from stent design (Medtronic tech transfer) to sterile packaging and air-cargo-compliant logistics.